DirectConnect

Inside Yale Cancer Cen

June 15, 2018

Announcements

Boffa Named Clinical Program Leader of TOP

Daniel J. Boffa, MD, Associate Professor of Surgery (Thoracic), has been named the Clinical Program Leader for the Thoracic Oncology Program (TOP) at Smilow Cancer Hospital. In this role, Dr. Boffa will work closely with Chief of Medical Oncology, Dr. Roy Herbst, Disease Aligned Research Team (DART) Leader and SPORE Leader for TOP, as they continue to grow the program and expand the treatment opportunities available for patients with lung and esophageal cancers at Smilow Cancer Hospital and our Care Centers. "I look forward to partnering with Dan as we continue to build out our Thoracic Oncology Program at our Tumor Boards and throughout the Smilow Network on the care of patients with thoracic malignancies," Dr. Herbst said.

CTO Transitions

After 6 years of outstanding leadership of the Data Safety and Monitoring Committee, Dr. Michal Rose has stepped down from her role to focus her time on other responsibilities at the VA Cancer Center. I would like to take this time to thank her for her extraordinary service to our clinical trials operations over the last several years.

To transition the leadership of the Data Safety and Monitoring Committee (DSMC), Dr. Daniel Petrylak will now chair the DSMC and transition from his position as current chair of the Protocol Review Committee (PRC). Dr. Barbara Burtness will now chair the PRC. I look

from the desk of Charles S. Fuchs, MD, MPH Director, Yale Cancer Center and Physician-in-Chief Smilow Cancer Hospital

Yale NewHaven **Health**

Smilow Cancer Hospital



News Center



forward to working with Drs. Petrylak and Burtness and appreciate their leadership on these committees.

ENT Leadership

It is with mixed emotions that we announce Wendell Yarbrough, Professor and Chief of the Section of Otolaryngology in the Department of Surgery, is leaving Yale to become Chair of the Department of Otolaryngology-Head and Neck Surgery at the University of North Carolina Chapel Hill. While we are proud of this accomplishment, we will miss Dr. Yarbrough who has been a valued member of our community since 2012. Under Dr. Yarbrough's tenure, the Section of Otolaryngology has grown with the addition of several faculty members and new clinical sites. This will be a coming home of sorts, as in addition to being a North Carolina native, Dr. Yarbrough obtained his undergraduate and medical degrees, was a resident, fellow, and then faculty member all at the University of North Carolina.

Benjamin Judson, currently Associate Professor and Vice-Chief for Clinical Affairs, will serve as Interim Chief of the Section of Otolaryngology. In addition, Dr. Judson will continue with his role as Chief Ambulatory Officer for Smilow Cancer Hospital.

ASCO Review Our faculty welcomed

over 200



colleagues to the New Haven Lawn Club this morning for our annual ASCO Review, hosted by Dr. Roy

From Patient to Participant: Wallingford Cancer Survivor to Ride in Closer to Free Read More >>



Extended Survival Observed in Patients With Solitary Brain Metastasis From RCC Read More >>



Following Guidelines for Healthy Eating and Physical Activity May Improve Survival in Patients Treated for Colon Cancer

Read more >>



Brain Tumor Program Hosts Patient Education Event Read More >>

Herbst, to provide updates on the latest information on oncology advances and clinical trials. 23 members of the Yale Cancer Center faculty will present throughout the day. Dr. Bruce Johnson, Chief Clinical Officer and Professor of Medicine at Dana-Farber Cancer Institute and President of ASCO will give the keynote presentation at 11:15am.


Learn More >>



I am pleased to announce that Kerin Adelson, MD has been appointed Chair of the Oncology Pharmacy and Therapeutics Committee. Kerin succeeds Dr. Rogerio Lilenbaum. I would like to thank Rogerio for his dedicated service and leadership on this committee over the past several years. In addition, Scott Huntington, MD will serve as Vice Chair. Dr. Hari Deshpande will remain on the committee and I thank him for his leadership as Vice Chair and appreciate his continued service to the committee.

Smilow Rocks


The kick-off of Smilow Rocks Project on Tuesday in the Healing Garden was a wonderful success. Special thanks to Dana Brewer, Creative Expression Coordinator at Smilow, volunteer Maureen Baldino, and their team of helpers for putting together an amazing display of hand-painted rocks for our patients, caregivers, and



Designated Cancer Centers Endorse Goal of Eliminating HPV-Related Cancers
Read More >>



Join Yale Cancer Center on Facebook



Latest Posts:

Smilow Cancer Hospital nutritionists recommend including a little extra protein in your diet to you stay strong throughout treatment.




More >>

Read more about the research by Yale's Goodman and Gillman in 1942 that led to the first use of chemotherapy at Yale New Haven Hospital, paving the way for many modern cancer therapies in today's #flashbackfriday article from the New Haven Register



Smilow at the Special Olympics

The 50th Annual Special Olympics CT was held last weekend and the Smilow Screening & Prevention Program was there to provide cancer screenings and distribute information to athletes, families, and volunteers. They were joined by members of Yale Dermatology, Yale Urology, and the Yale Center for Clinical Investigation, as well as the Yale New Haven Hospital Mammography van, which provided free mammograms to the athletes. Thank you to all of the physicians and staff who volunteered their time to make the day a success!



Read More >>

Just a few of the smiling faces and amazing stories of cancer survivorship on our website. Take a minute to read their stories and learn more about their journeys through cancer treatment and survivorship.



Read More >>

Congratulations to Dr. Roy Herbst, Chief of Medical Oncology at Smilow Cancer Hospital, who was named a Fellow of the American Society of Clinical Oncology.



Read More >>

Despite the hardships Roslyn Goldstein experienced early in life, a sense of responsibility drove her to contribute \$500,000 to the Yale Cancer Center Discovery Fund. The fund was created to advance fundamental scientific research that



will ultimately reap clinical innovations.



Read More >>

Follow us on twitter

Follow Yale Cancer Center on Twitter

Although patients who develop brain metastases from renal cell carcinoma typically have poor outcomes, investigators from @YaleCancer have identified a subset of patients who demonstrated extended survival.

One message can change your whole day, outlook or life! @theKindnessrock decorated with inspirational messages for #cancerpatients, their families and caregivers were on display in our #healinggarden at Smilow Cancer Hospital

In an interview with the @ASCOPost@CharlesFuchsMDsays a healthy approach to lifestyle increases survival for colon cancer patients.

The Guilford Senior Citizens Program recently hosted Dr. Preston Sprenkle who spoke about #prostatecancer and covered a variety of urology topics during the Q&A session, including #PSAtests

Listen to Dr. Terri Parker & Dr. Steven Gore discuss the latest advances in Multiple Myeloma treatments on Yale Cancer

Notables

Oligo Nation and Operation Oligo have awarded Ranjit Bindra, MD, PhD, Associate Professor of Therapeutic Radiology and a member of Yale Cancer Center's Radiobiology and Radiotherapy Research Program, a research grant in the amount of \$125,000 to support his project entitled, "Targeting IDHI Mutant Oligodendroglioma with CNS-Permeable PARP Inhibitor."

Roy S. Herbst, MD, PhD, Chief of Medical Oncology, gave the opening lecture at the World Congress on Interventional Oncology meeting in Boston last weekend on the importance of precision medicine in oncology.

Development Updates

Roberta Lombardi, from Madison, CT, wanted to give back to the Breast Center in a gesture of gratitude and admiration. She created the Infinite Strength organization with the mission to make medical treatments more accessible for all breast cancer patients and to offset costs that are not always covered by insurance, but can make all the difference in the

healing process, both physically and emotionally. Roberta hosted the first annual Evening in Pink at Pine Orchard Yacht and Country Club in Branford, CT on Saturday, May 12, raising \$50,000 for the Smilow Cancer Hospital Scalp Cooling program and for patients with breast cancer needing additional financial assistance.



Roberta Lombardi (seated center), presents donation from the proceeds of her Evening In Pink Gala to Dr. Brigid Killelea, Dr. Sarah Mougalian, and members of the Boutique and Breast Center staff.

Answers today at 7:30pm on @wnpr or online at http://www.wnpr.org.

Dr. Lajos Pusztai and Dr. Erin Hofstatter answered questions and cheered on all of the amazing @SusanGKomen@KomenNewEng walkers this morning. Thank you to everyone who participated for your support!

Our Screening and Prevention Program was proud to partner with .@SOCTconnecticut to offer athletes and their families #screenings#mammograms and health information today. Good luck at your events this weekend!

@Yalecancer supports @ACSto get teens vaccinated for #HPVand age-eligible women screened for #cervicalcancer.

Thank you to our faculty and to @ctbta and the Lovemark Foundation for their support of our #braintumor program this evening. Presentation videos will be shared soon.

@CharlesFuchsMD from @YaleCancer d elivers a fantastic video update at #ASCO18 on the KEYNOTE-061 trial #GastricCancer

Important data from the SHAVE trial @YaleCancer

Combination
of #RadiationTherapy and #Immunotherapy f
or #LungCancer- unanswered questionsdose, schedule, site, timing, biomarkers,
abscopal effect etc- Dr. Sarah Goldberg

2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago

Dr. Bruce Johnson now discussing the importance of immunotherapy for patients with lung cancer with a focus on the basic scientific discoveries that led the way @YaleCancer



The Infinite Strength board includes (left) Eric Conti, President and Founder Roberta Lombardi, Sarah Mougalian, MD and Austin Miller.

The Jim McNiff Memorial Golf Tournament has provided \$23,400 in support of Dr. Harriet Kluger's Renal Research Fund. The annual golf tournament began in 2012 to support kidney cancer research in memory of Jim McNiff, who passed away from complications of kidney cancer in 2008.

Calendar

Yale CME / Digestive Disease Conference June 15; 7AM

Water's Edge Resort

13th Annual Yale Digestive Disease Week Review

Priya A Jamidar, FACG, FASGE, MBChB and Harry Aslanian, MD

Learn More >>

William F. Collins Jr., MD, Neurosurgery Resident Research Symposium

June 15; 3PM

TAC N107

Integrating Stem Cell Science Into Brain Cancer Research

Viviane Tabar, MD

Learn More >>

Smilow Screening & Prevention Program Event

June 16; 8AM

Local Barbershops

Yale African American Affinity / Men's Health Day Event

Learn More >>

Yale Cancer Answers June 17; 7:30PM

WNPR

Men's Health Month

Michael S Leapman, MD

Learn More >>

Radiobiology and Radiotherapy Research Program

June 18; 11AM

BCMM 206/208

Characterization of Poly (ADP-Ribose) Polymerase Inhibitors for Targeted Use in DNA Repair Deficient Cancers

Greg Breuer



Mrs. McNiff and Harriet Kluger.

Employee Profile: Sarah Perreault

In her role as a Clinical Pharmacy Specialist for the Bone Marrow Transplant Program, Sarah Perreault, PharmD. BCPS, BCOP works in both the inpatient and outpatient setting. Driven by an experience with

cancer in her



own family, Sarah decided to specialize in oncology at the Mayo Clinic after completing pharmacy school, and has now been at Smilow for the last five years.

Learn More >>

YCC Genomics, Genetics and Epigenetics Research Program

June 18; 1PM

SHM I-304

Investigating Non-genetic Determinants of Cancer Progression in Mice

Mandar D Muzumdar, MD

Learn More >>

Pathology Research in Progress Talks June 19; 9:30AM

TAC N-107

Methylation Landscapes Underlying Human Aging and Disease

Morgan Levine, PhD

TBA

Shang-Min Zhang, PhD

Learn More >>

YCC Grand Rounds

June 19: 12PM

Park Street Auditorium

Changing the Outcome of Pancreatic Cancer Nita Ahuja, MD, MBA

Innate Immune Checkpoints in Anti-tumor Immunity

Carla Rothlin, PhD

Learn More >>

Palliative Care Conference

June 19; 4PM

FMP 618

Moving from Emergency / Critical Care Medicine to Palliative Care: A Treatment and Career Trajectory

Catherine Glazer

Prognostication in the Critically III Cancer Patient - A Case of Novel Therapy Challenging the Status Quo

Dmitry Kozhevnikov

Learn More >>

Interventional Radiology Grand Rounds Lecture

Patients that are undergoing transplants have very complex treatment regimens that occur over a long period of time, and Sarah follows them closely throughout, providing chemotherapy and other medications. As they move from the inpatient to the outpatient setting, she monitors for any drug interactions or side effects, and provides supportive care as needed. Sarah commented that the entire team works together to provide the best care possible for each patient.

"We all specialize in different areas and use that diverse knowledge to benefit our patients. It is like one big family surrounding every patient," said Sarah. "We follow these patients over the course of their entire transplant, and I also work to educate them about what to expect during transplant and after."

One of the things Sarah enjoys most about oncology is the always changing environment and the fact that she is constantly learning and growing within her role. Osama Abdelghany, PharmD, BCOP, Manager, Oncology Pharmacy Services, commented, "Sarah is passionate about improving patient care and advancing the practice of oncology pharmacy. She goes above and beyond to ensure the best patient care possible. She is also an outstanding teacher and a mentor, and under her direction and leadership, our oncology pharmacy residency program is recognized as one of the best in the country."

Funding Opportunities

NIH Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research-R21

This FOA represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce.

Application Deadline: June 19, 2018

Learn More >>

PREVENT Cancer Preclinical Drug Development Program RFP

The NCI has issued a RFP to support the PREVENT Cancer Preclinical Drug Development Program: Preclinical Services for Biopharmaceutical Product

June 20: 7:30AM

Fitkin Auditorium

Strategies for Precision-Guided Interventions in Hepatocellular Carcinoma

Terence P. Gade, MD, PhD

Learn More >>

Smilow Cancer Genetics and Prevention Program Seminar

June 21; 2:30PM

SRC, suites 107-109

Learn More >>

Smilow Wellness Workshop

June 21; 9AM

Park Street Seminar Room

Embracing Uncertainty: Opening to Infinite Possibilities

Mel Schwartz, LCSW, MPhil

Learn More >>

Smilow Pediatric Cancer Survivors Day

June 24; 12PM

Edgerton Park

Blast off to the Survivorship Picnic

Learn More >>

Yale Cancer Answers

June 24; 7:30PM

WNPR

Surgical Care for Thyroid Cancer

Courtney Gibson, MD, MS

Learn More >>

Yale HIV Symposium

June 25; 7:30AM

TAC

Learn More >>

Hematology Special Seminar

June 25; 11AM

BCMM 206/208

Genetic Predictors and Curative Therapies for Clinically Aggressive Sickle Cell Disease

Santosh Saraf, MD

Development and Manufacturing, Toxicology and Pharmacology Testing. The overall objective of the current acquisition is to provide a structured approach to drug and vaccine development, from discovery to the clinic.

Application Deadline: June 21, 2018

Read More >>

Research Answers to NCI's Provocative Questions - R21 and R01

The purpose of this FOA is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative.

Application Deadline: June 29, 2018

Learn More >>

Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award: Clinical, Health Services and Policy Research

Two-year Awards of \$90,000 (\$45,000 per year) will be awarded to applicants working in Connecticut, New Jersey and Rhode Island.

Application Deadline: July 3, 2018

Learn More >>

Multidisciplinary Studies of HIV/AIDS and Aging (R01/R21)

These FOAs encourage exploratory/developmental research applications at the intersection of HIV and aging.

Application Deadlines: July 5, 2018(R01) July 16, 2018(R21)

Learn More >>

Damon Runyon-Rachleff Innovation Award

Designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

Application Deadline: July 6, 2018

Learn More >>

Learn More >>

YCC Obesity and Cancer Research Working Group

June 26; 12PM

YSPH

Melinda Irwin, PhD, MPH

Learn More >>

Schwartz Center Rounds

June 26; 12PM

55 Park Street

Learn More >>

Human and Translational Immunology Seminars

June 26; 4PM

TAC N-203

Immuno-oncology Vulnerabilities and Opportunities Stemming from Lymphocyte Ambivalence

Steven Reiner, MD

Learn More >>

Grand Rounds for Non-Clinicians

June 27; 12PM

55 Park Street Auditorium

The Next Chapter for Yale Cancer Center and Smilow Cancer Hospital: A Vision for the

Charles Fuchs, MD, MPH

Learn More >>

YCC/SCH Liver Cancer Symposium

June 27; 5:30PM

Mystic Marriott

Improving Liver Cancer Surveillance and Treatment Options for Patients

Mario Strazzabosco, MD, PhD anad Stacey Stein, MD

Learn More >>

Immunobiology Seminar Series

June 28; 10:30AM

TAC N107

Program in Innovative Therapeutics for Connecticut's Health (PITCH)

With a grant from the State of Connecticut's Bioscience Innovation Fund, this three-year, \$10 million-dollar program, provides translational research resources to generate prototype therapeutics that address unmet clinical needs. Contact francine.carland@yale.edu for more information.

Application Deadline: July 15, 2018

Learn More >>

Bonnie J. Addario Lung Cancer Foundation/Van Auken Private Foundation Young Innovators Team Awards

ALCF, in collaboration with VAPF, is requesting applications from teams of young investigators that address unmet medical needs in lung cancer patient-oriented research. High-risk, high-reward, multidisciplinary, collaborative research projects that are currently unfunded will be awarded \$250,000 for a period of 2-3 years (depending on the proposed research).

Application Deadline: July 15, 2018

Learn More >>

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries R21

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS.

Application Deadline: August 1, 2018

Learn More >>

HIV/AIDS and the Tumor Niche (R01)

The purpose of this FOA is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or AIDS.

T Lymphocyte Diversity: Matching Specificity and Function

Federica Sallusto, PhD

Learn More >>

Pharmacology Seminar Series

June 28; 12:30PM

BML 131

Divide and Conquer: New Approaches to

Disrupt Raf Kinase Signaling
Deborah Morrison, PhD

Learn More >>

Smilow Cancer Genetics and Prevention Program Seminar

June 28; 2:30PM

SRC, suites 107-109

Learn More >>

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Application Deadline: August 7, 2018

Learn More >>

DoD Prostate Cancer Research Program Opportunities

- Idea Development Award: This Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. Pre-Application Deadline: July 6, 2018
- Impact Award: This Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues and is intended for independent investigators at or above the level of Assistant Professor (or equivalent). Pre-Application Deadline: July 19, 2018
- Physician Research Award: This Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Pre-Application Deadline: August 16, 2018
- Early Investigator Research Award: This Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. Pre-Application Deadline: August 16, 2018

Learn More >>

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (R01/R21)

The purpose of the FOA is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus; the biology of the initial steps of infection; and risk factors for infection in populations living with HIV or at high risk of developing HIV.

Application Deadline: August 18, 2018

Learn More >>

DoD Kidney Cancer Research Program Funding Opportunities for 2018

- Concept Award: To support highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Letter of Intent Due: July 11, 2018
- Idea Development Award: To support new ideas that represent innovative, high-risk/highgain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. Letter of Intent Due: September 5, 2018
- Physicians Research Award: To support a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research. Letter of Intent Due: September 5, 2018
- Technology Development Award: To support emerging technologies to aid clinical and patient outcomes. Letter of Intent Due: September 5, 2018
- Translational Research Partnership: To support partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. Letter of Intent Due: September 5, 2018

Learn More >>

Recent Publications

Local Option: The Rational Use of Local Therapy in Patients at High Risk to Die of Metastatic Progression.

Boffa DJ.

J Oncol Pract. 2018 Jun;14(6):344-349.

Read More >>

Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining CancerIncidence in HIV-Infected Veterans: A Prospective Cohort Study.

Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Bedimo RJ, Justice AC, Dubrow R.

Ann Intern Med. 2018 Jun 12.

Read More >>

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD.

Blood Cancer J. 2018 Jun 11;8(6):55.

Read More >>

Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS.

Cancer. 2018 Jun 11.

Read More >>

SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior.

Brown TC, Murtha TD, Rubinstein JC, Korah R, Carling T

Cell Commun Signal. 2018 Jun 8;16(1):27.

Read More >>

Practice Patterns and Perceptions of Chest Health Care Providers on Electronic Cigarette Use: An In-Depth Discussion and Report of Survey Results.

Baldassarri SR, Chupp GL, Leone FT, Warren GW, Toll BA.

J Smok Cessat. 2018 Jun;13(2):72-77.

Read More >>

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jun 4. pii: S0140-6736(18)31257-1.

Read More >>

Barriers and facilitators to implementing the commission on cancer's distress screening program standard.

Knies AK, Jutagir DR, Ercolano E, Pasacreta N, Lazenby M, McCorkle R.

Palliat Support Care. 2018 Jun 8:1-9.

Read More >>

Scarless genome editing: progress towards understanding genotype-phenotype relationships.

Elison GL, Acar M.

Curr Genet. 2018 Jun 5.

Read More >>

A case-control study of exposure to organophosphate flame retardants and risk of thyroid cancer in women.

Deziel NC, Yi H, Stapleton HM, Huang H, Zhao N, Zhang Y.

BMC Cancer. 2018 Jun 5;18(1):637.

Read More >>

The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.

Morse E, Fujiwara RJT, Mehra S.

Otolaryngol Head Neck Surg. 2018 Jun 1:194599818774739.

Read More >>

The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses.

Kim H, Lin Q, Yun Z.

Cancer Lett. 2018 May 30;431:142-149.

Read More >>

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.

Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, Song Y, Vasic R, Maziarz J, Balasubramanian K, Ardasheva A, Ding A, Quattrone A, Halene S. Leukemia. 2018 Jun 1.

Read More >>

Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.

Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL.

Lab Invest. 2018 Jun 1.

Read More >>

ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.

Wilson FH, Politi K.

Cancer Discov. 2018 Jun;8(6):676-678.

Read More >>